注册号: Registration number: |
ChiCTR-IOR-17013568 |
最近更新日期: Date of Last Refreshed on: |
2020-05-10 |
注册时间: Date of Registration: |
2017-11-27 |
注册号状态: |
预注册 |
Registration Status: |
Prospective registration |
注册题目: |
急性缺血性卒中直接血管内治疗与桥接治疗的比较 |
Public title: |
Direct Endovascular Treatment versus Bridging Therapy for Patients with Acute Ischemic Stroke |
注册题目简写: |
DEVT |
English Acronym: |
DEVT |
研究课题的正式科学名称: |
比较直接血管内治疗与桥接治疗发病4.5小时内急性前循环大动脉闭塞性卒中的多中心、随机临床试验 |
Scientific title: |
Multicenter Randomized Trial of Direct endovascular treatment versus bridging therapy for Acute Ischemic Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting within 4.5 Hours of Symptom Onset. |
研究课题代号(代码): Study subject ID: |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
申请注册联系人: |
杨清武 |
研究负责人: |
杨清武 |
Applicant: |
Qingwu Yang |
Study leader: |
Qingwu Yang |
申请注册联系人电话: Applicant telephone: |
+86 13657638868 |
研究负责人电话: Study leader's telephone: |
+86 13657638868 |
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
申请注册联系人电子邮件: Applicant E-mail: |
yangqwmlys@163.com |
研究负责人电子邮件: Study leader's E-mail: |
yangqwmlys@163.com |
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
申请注册联系人通讯地址: |
重庆市沙坪坝区新桥正街183号 |
研究负责人通讯地址: |
重庆市沙坪坝区新桥正街183号 |
Applicant address: |
183 Xinqiao Main Street, Shapingba District, Chongqing, China |
Study leader's address: |
183 Xinqiao Main Street, Shapingba District, Chongqing, China |
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
申请人所在单位: |
第三军医大学新桥医院 |
||
Applicant's institution: |
Xinqiao Hospital, the Third Military Medical University |
是否获伦理委员会批准: |
是 |
||
Approved by ethic committee: |
Yes |
||
伦理委员会批件文号: Approved No. of ethic committee: |
ChiECRCT-20170101 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
批准本研究的伦理委员会名称: |
中国注册临床试验伦理审查委员会 |
||
Name of the ethic committee: |
Chinese Ethics Committee of Registering Clinical Trials |
||
伦理委员会批准日期: Date of approved by ethic committee: |
2017-12-27 | ||
伦理委员会联系人: |
米娜 |
||
Contact Name of the ethic committee: |
Mina |
||
伦理委员会联系地址: |
中国香港特别行政区九龙塘浸会大学中国临床试验注册中心香港中心 |
||
Contact Address of the ethic committee: |
Chinese Clinical Trial Registry Hong Kong Center, Hong Kong Baptist University, Hong Kong SAR, China |
||
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
研究实施负责(组长)单位: |
第三军医大学新桥医院 |
||||||||||||||||||||||
Primary sponsor: |
Xinqiao Hospital, the Third Military Medical University |
||||||||||||||||||||||
研究实施负责(组长)单位地址: |
重庆市沙坪坝区新桥正街183号 |
||||||||||||||||||||||
Primary sponsor's address: |
183 Xinqiao Main Street, Shapingba District, Chongqing, China |
||||||||||||||||||||||
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
经费或物资来源: |
国家杰出青年科学基金之医院匹配经费 |
||||||||||||||||||||||
Source(s) of funding: |
Hospital matching funds of The National Science Fund for Distinguished Young Scholars |
||||||||||||||||||||||
研究疾病: |
急性缺血性卒中 |
||||||||||||||||||||||
Target disease: |
acute ischemic stroke |
||||||||||||||||||||||
研究疾病代码: |
|
||||||||||||||||||||||
Target disease code: |
|
||||||||||||||||||||||
研究类型: |
干预性研究 |
||||||||||||||||||||||
Study type: |
Interventional study |
||||||||||||||||||||||
研究所处阶段: |
其它 | ||||||||||||||||||||||
Study phase: |
N/A |
||||||||||||||||||||||
研究目的: |
在发病4.5h内前循环大动脉闭塞性卒中患者人群中,比较直接血管内治疗与桥接治疗两种治疗方案的有效性及安全性。 |
||||||||||||||||||||||
Objectives of Study: |
To investigate the differences in effectiveness and safety between direct endovascular treatment and bridging therapy in acute ischemic stroke patients due to large artery occlusion in the anterior circulation within 4.5 h of stroke onset. |
||||||||||||||||||||||
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
研究设计: |
随机平行对照 |
||||||||||||||||||||||
Study design: |
Parallel |
||||||||||||||||||||||
纳入标准: |
1) 年龄18周岁以上; 2) 根据临床症状或影像检查初步判断为前循环缺血性脑卒中; 3) CTA/MRA/DSA证实颈内动脉颅内段、大脑中动脉M1段; 4) 符合r-tPA静脉溶栓标准; 5) 从发病到随机化时间在4.25h内; 6) 患者或家属签署书面知情同意书。 |
||||||||||||||||||||||
Inclusion criteria |
1) Aged 18 years or older; 2) Anterior circulation acute ischemic stroke confirmed by clinical symptoms or imaging examination; 3) I-ICA or MCA-M1 occlusion proved by CTA/MRA/DSA; 4) Eligible for intravenous thrombolysis with r-tPA; 5) Time from stroke onset to randomization within 4.25h; 6) Written informed consent is obtained from patients and/or their legal representatives. |
||||||||||||||||||||||
排除标准: |
1) 颅内出血; 2) 有静脉溶栓禁忌症; 3) 发病前mRS评分≥2分; 4) 妊娠或哺乳期妇女; 5) 对造影剂、镍、钛或镍钛合金过敏; 6) 动脉迂曲致取栓装置无法到达目标血管; 7) 既往神经系统或精神疾病导致神经功能评估障碍; 8) 多个血管闭塞(例如双侧前循环闭塞或前后循环同时闭塞); 9) 影像学上排除具有占位效应的脑肿瘤; 10) 脑血管炎 11) 颅内动脉瘤、动静脉畸形; 12) 任何疾病晚期导致预期寿命少于6个月; 13) 预期不能完成90天随访; 14) 正在参加其他临床试验。 |
||||||||||||||||||||||
Exclusion criteria: |
1) Intracranial hemorrhage; 2) Contraindications of IV rt-PA; 3) Pre-stroke disability mRS score >= 2; 4) Pregnancy or lactating women; 5) Known sensitivity to radiographic contrast agents, nickel, titanium metals or their alloys;; 6) Arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel; 7) Patients with a preexisting neurological or psychiatric disease that would confound the neurological functional evaluations; 8) Subjects with occlusions in multiple vascular territories (e.g. bilateral anterior circulation, or anterior/posterior circulation); 9) CT or MRI evidence of mass effect or intracranial tumor (except small meningioma); 10) CT or MRI evidence of cerebral vasculitis; 11) CTA or MRA evidence of intracranial arteriovenous malformations or aneurysms; 12) Any terminal illness with life expectancy less than 6 months; 13) Unlikely to be available for 90-day follow-up; 14) Current participation in another clinical trial. |
研究实施时间: Study execute time: |
从From2017-12-01至To 2021-09-01 |
征募观察对象时间: Recruiting time: |
从From2018-05-01至To 2021-06-01 |
干预措施: Interventions: |
|
研究实施地点: Countries of recruitment and research settings: |
|
测量指标: Outcomes: |
|